Welcome to our dedicated page for Versigent news (Ticker: VGNT), a resource for investors and traders seeking the latest updates and insights on Versigent stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Versigent's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Versigent's position in the market.
Versigent (NYSE: VGNT) reported second-quarter 2026 net sales of $2,444 million, up 10.8% year-over-year, with Adjusted Net Sales Growth of about 5%. Net income attributable to Versigent rose to $118 million and diluted EPS to $1.64, while Adjusted Diluted EPS reached $1.92. Adjusted EBITDA increased 24.8% to $272 million, expanding margin to 11.1%, up 120 basis points.
Net cash from operating activities was $158 million, and Free Cash Flow was $107 million, including $22 million of separation-related costs. The Board declared an inaugural quarterly dividend of $0.13 per share, payable September 18, 2026. Versigent raised full-year 2026 net sales guidance to $9.4–$9.6 billion, while reaffirming Adjusted EBITDA guidance of $950–$1,030 million and Free Cash Flow guidance of $200–$300 million.
Versigent (NYSE: VGNT) will release its Q2 2026 financial results before the New York Stock Exchange opens on Tuesday, August 4, 2026. Management will discuss the results on a conference call at 9:00 a.m. Eastern Time, hosted by CEO Joe Liotine and CFO Doug Ostermann.
A live webcast and presentation materials will be available on Versigent’s Investor Relations website (ir.versigent.com), with a replay accessible about two hours after the call. Investors can also join by telephone using U.S. dial-in +1-800-330-6710 or international dial-in +1-213-279-1505, referencing conference ID 1768848.
Versigent (NYSE: VGNT) announced management participation in two June 2026 investor conferences in New York City.
Events include the UBS Auto and Auto Tech Conference on June 3, 2026, featuring a webcast fireside chat, and the Wolfe Research Autos and Mobility Conference on June 18, 2026.
Versigent (NYSE: VGNT) reported First Quarter 2026 results: revenue $2,212M (+9%), net income attributable to Versigent $78M, adjusted EBITDA $203M (9.2% margin), and free cash flow $(30)M. The company reaffirmed full‑year 2026 guidance: revenue $9,100–$9,400M, U.S. GAAP net income $315–$375M, adjusted EBITDA $950–$1,030M, and free cash flow $200–$300M.
In April 2026 the board approved a $0.13 per share quarterly dividend policy (to be declared) and a $250M share repurchase program.
Versigent (NYSE: VGNT) will release first quarter 2026 results on May 5, 2026 after market close and host a conference call at 4:15 p.m. ET the same day.
The call will be led by CEO Joe Liotine and CFO Doug Ostermann, with a live webcast, presentation materials and a replay available on the Versigent Investor Relations website. Q1 results are presented on a carve-out basis from Aptiv historical accounting, consistent with Versigent's Form 10 registration.
Versigent (NYSE: VGNT) launched as an independent public company on April 1, 2026, following a tax-free spin-off from Aptiv. Shares begin trading under VGNT and leadership rang the NYSE Opening Bell.
Versigent starts with $8.8B revenue, $528M net income, and $893M adjusted EBITDA for 2025, expects >3% top-line growth, plans >200 bps EBITDA margin expansion over three years, and targets $1B free cash flow by 2028. Distribution: one Versigent share per three Aptiv shares; fractional-share cash paid. First-quarter results due May 5, 2026.
Aptiv (NYSE: APTV) will release Q1 2026 financial results on May 5, 2026 prior to market open and hold an investor call at 8:00 a.m. ET. Results will report Total Aptiv with Electrical Distribution Systems (EDS) as a segment.
Versigent (NYSE: VGNT), the EDS carve-out expected to spin off on April 1, 2026, will release Q1 2026 results on May 5, 2026 following market close and host a call at 4:15 p.m. ET. Webcasts, presentation materials, replays, and dial-in details are available on each company’s investor relations site.
Versigent (NYSE:VGNT) will be added to the S&P SmallCap 600 prior to the open on April 2, 2026, replacing Titan International (NYSE:TWI). The spin-off of Versigent from Aptiv (NYSE:APTV) is expected to complete on April 1, 2026, with Aptiv remaining in the S&P 500.
S&P Dow Jones Indices cited Titan's market capitalization as no longer representative of the small-cap market, prompting the deletion and index reconstitution.